Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 6 of 39, showing 5 Applications out of 191 total, starting on record 26, ending on 30

# Protocol No Study Title Investigator(s) & Site(s)

26.

ECCT/24/03/04   MK8591A-053 Trial
    A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
2. Nelly Rwamba Mugo
Site(s) in Kenya
1. Site 8650, KEMRI-CMR-RCTP, Kisumu (Kisumu county)
2. Site 8651, KEMRI-CCR-PHRD, Thika (Kiambu county)
3. Site 8652, KEMRI-CCR, NAIROBI (Nairobi City county)
 
View

27.

ECCT/24/03/02   PEARL RSVt Vaccine Study
    Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL   
Principal Investigator(s)
1. Dr. Janet Nyawira Oyieko
Site(s) in Kenya
1. KEMRI CCR – Butere Clinical Research Centre (Kakamega county)
 
View

28.

ECCT/24/02/10   IMBrave
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB, WITH OR WITHOUT TIRAGOLUMAB, IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA   
Principal Investigator(s)
1. Dr. Pauline Njoki Njiraini
Site(s) in Kenya
University of Nairobi -Institute of Tropical and Infectious Diseases
 
View

29.

ECCT/24/02/09   pionERA
    This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of   giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor   (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal   growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant   endocrine therapy.   
Principal Investigator(s)
1. Dr Sitna Ali
Site(s) in Kenya
University of Nairobi -Institute of Tropical and Infectious Diseases
 
View

30.

ECCT/24/02/07   CO-SAM
          An adaptive multi-arm trial to improve clinical outcomes among children recovering from complicated severe acute malnutrition (CO-SAM)             
Principal Investigator(s)
1. Benson Singa
Site(s) in Kenya
1. Homabay County Referral hospital (Homa Bay county)
2. Migori County Referral Hospital (Migori county)
3. Mbagathi County Referral Hospital (Nairobi City county)
4. Coast General Teaching and Referral Hospital (Mombasa county)
 
View